Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Purpose Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.Materials and methods This post-hoc analysis further examined MAVORIC data to assess factors associated...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2438794 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567415336075264 |
|---|---|
| author | Francine Foss Youn H. Kim Julia Scarisbrick Oleg Akilov Robert Ristuccia Karen Dwyer Wende Wu Martine Bagot |
| author_facet | Francine Foss Youn H. Kim Julia Scarisbrick Oleg Akilov Robert Ristuccia Karen Dwyer Wende Wu Martine Bagot |
| author_sort | Francine Foss |
| collection | DOAJ |
| description | Purpose Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.Materials and methods This post-hoc analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.Results A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vs. vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 vs. 3.1 months; p < 0.0001) in mogamulizumab vs. vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT vs. vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.Conclusions MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR. |
| format | Article |
| id | doaj-art-eb78ed5180e54eb4908ac51a85406811 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-eb78ed5180e54eb4908ac51a854068112025-02-03T01:01:43ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2024.2438794Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumabFrancine Foss0Youn H. Kim1Julia Scarisbrick2Oleg Akilov3Robert Ristuccia4Karen Dwyer5Wende Wu6Martine Bagot7Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USAStanford University, Stanford, CA, USAInstitute of Immunology and Immunotherapy, University Hospitals Birmingham, University of Birmingham, Birmingham, UKDepartment of Dermatology, University of Pittsburgh, Pittsburgh, PA, USAKyowa Kirin, Inc., Princeton, NJ, USAKyowa Kirin, Inc., Princeton, NJ, USAKyowa Kirin, Inc., Princeton, NJ, USAHôpital Saint Louis, APHP, Inserm U976, Université Paris Cité, Paris, FrancePurpose Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.Materials and methods This post-hoc analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.Results A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vs. vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 vs. 3.1 months; p < 0.0001) in mogamulizumab vs. vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT vs. vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.Conclusions MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.https://www.tandfonline.com/doi/10.1080/09546634.2024.2438794Cutaneous T-cell lymphomamycosis fungoidesSézary syndromemogamulizumabC-C chemokine receptor 4 |
| spellingShingle | Francine Foss Youn H. Kim Julia Scarisbrick Oleg Akilov Robert Ristuccia Karen Dwyer Wende Wu Martine Bagot Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab Journal of Dermatological Treatment Cutaneous T-cell lymphoma mycosis fungoides Sézary syndrome mogamulizumab C-C chemokine receptor 4 |
| title | Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab |
| title_full | Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab |
| title_fullStr | Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab |
| title_full_unstemmed | Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab |
| title_short | Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab |
| title_sort | insights into treatment of patients with mycosis fungoides or sezary syndrome using mogamulizumab |
| topic | Cutaneous T-cell lymphoma mycosis fungoides Sézary syndrome mogamulizumab C-C chemokine receptor 4 |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2438794 |
| work_keys_str_mv | AT francinefoss insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab AT younhkim insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab AT juliascarisbrick insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab AT olegakilov insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab AT robertristuccia insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab AT karendwyer insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab AT wendewu insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab AT martinebagot insightsintotreatmentofpatientswithmycosisfungoidesorsezarysyndromeusingmogamulizumab |